Sanofi and GSK begin Phase II Covid-19 vaccine candidate study
Sanofi and GlaxoSmithKline (GSK) have initiated a Phase II dose-finding study of their adjuvanted recombinant protein-based Covid-19 vaccine candidate.
Panama
Latest in
Panama
Turn Therapeutics gets authorisation for Covid-19 therapeutic candidate trial
Biotechnology company Turn Therapeutics has received authorisation in Panama to begin the human trial of its product, Hexagen, for treating…
FDA finds Moderna’s Covid-19 vaccine to have no specific safety concerns
The US Food and Drug Administration (FDA) has stated in its briefing document that Moderna’s experimental Covid-19 vaccine, mRNA-1273, is…